|
1
|
Berezikov E, Cuppen E and Plasterk RHA:
Approaches to microRNA discovery. Nat Genet. 38 (Suppl):S2–S7.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neely LA, Patel S, Garver J, Gallo M,
Hackett M, McLaughlin S, Nadel M, Harris J, Gullans S and Rooke J:
A single-molecule method for the quantitation of microRNA gene
expression. Nat Methods. 3:41–46. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shyu AB, Wilkinson MF and van Hoof A:
Messenger RNA regulation: To translate or to degrade. EMBO J.
27:471–481. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Callis TE, Chen JF and Wang DZ: MicroRNAs
in skeletal and cardiac muscle development. DNA Cell Biol.
26:219–225. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giannakakis A, Coukos G, Hatzigeorgiou A,
Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human
cancers. Exp Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar
|
|
8
|
Hatfield S and Ruohola-Baker H: microRNA
and stem cell function. Cell Tissue Res. 331:57–66. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi K, Yan I, Wen HJ and Patel T:
microRNAs in liver disease: From diagnostics to therapeutics. Clin
Biochem. 46:946–952. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tomimaru Y, Eguchi H, Nagano H, Wada H,
Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M,
Umeshita K, et al: MicroRNA-21 induces resistance to the
anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular
carcinoma cells. Br J Cancer. 103:1617–1626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karakatsanis A, Papaconstantinou I,
Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of
microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,
miR-221, miR-222, and miR-223 in patients with hepatocellular
carcinoma or intrahepatic cholangiocarcinoma and its prognostic
significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bommer GT, Gerin I, Feng Y, Kaczorowski
AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang TC, Wentzel EA, Kent OA,
Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M,
Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53
broadly influences gene expression and promotes apoptosis. Mol
Cell. 26:745–752. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Raver-Shapira N, Marciano E, Meiri E,
Spector Y, Rosenfeld N, Moskovits N, Bentwich Z and Oren M:
Transcriptional activation of miR-34a contributes to p53-mediated
apoptosis. Mol Cell. 26:731–743. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tarasov V, Jung P, Verdoodt B, Lodygin D,
Epanchintsev A, Menssen A, Meister G and Hermeking H: Differential
regulation of microRNAs by p53 revealed by massively parallel
sequencing: miR-34a is a p53 target that induces apoptosis and
G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ichimura A, Ruike Y, Terasawa K, Shimizu K
and Tsujimoto G: MicroRNA-34a inhibits cell proliferation by
repressing mitogen-activated protein kinase kinase 1 during
megakaryocytic differentiation of K562 cells. Mol Pharmacol.
77:1016–1024. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Di Martino MT, Leone E, Amodio N, Foresta
U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli
E, et al: Synthetic miR-34a mimics as a novel therapeutic agent for
multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res.
18:6260–6270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li L, Xie X, Luo J, Liu M, Xi S, Guo J,
Kong Y, Wu M, Gao J, Xie Z, et al: Targeted expression of miR-34a
using the T-VISA system suppresses breast cancer cell growth and
invasion. Mol Ther. 20:2326–2334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pang RT, Leung CO, Lee CL, Lam KK, Ye TM,
Chiu PC and Yeung WS: MicroRNA-34a is a tumor suppressor in
choriocarcinoma via regulation of Delta-like1. BMC Cancer.
13:252013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guessous F, Zhang Y, Kofman A, Catania A,
Li Y, Schiff D, Purow B and Abounader R: microRNA-34a is tumor
suppressive in brain tumors and glioma stem cells. Cell Cycle.
9:1031–1036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo YP, Zhou H, Krueger J, Kaplan C, Liao
D, Markowitz D, Liu C, Chen T, Chuang TH, Xiang R and Reisfeld RA:
The role of proto-oncogene Fra-1 in remodeling the tumor
microenvironment in support of breast tumor cell invasion and
progression. Oncogene. 29:662–673. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Li J, Dong K, Lin F, Long M,
Ouyang Y, Wei J, Chen X, Weng Y, He T and Zhang H: Tumor suppressor
miR-34a targets PD-L1 and functions as a potential
immunotherapeutic target in acute myeloid leukemia. Cell Signal.
27:443–452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thor T, Künkele A, Pajtler KW, Wefers AK,
Stephan H, Mestdagh P, Heukamp L, Hartmann W, Vandesompele J,
Sadowski N, et al: miR-34a deficiency accelerates medulloblastoma
formation in vivo. Int J Cancer. 136:2293–2303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gallardo E, Navarro A, Viñolas N, Marrades
RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez
J and Monzo M: miR-34a as a prognostic marker of relapse in
surgically resected non-small-cell lung cancer. Carcinogenesis.
30:1903–1909. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fang C, Zhu DX, Dong HJ, Zhou ZJ, Wang YH,
Liu L, Fan L, Miao KR, Liu P, Xu W and Li JY: Serum microRNAs are
promising novel biomarkers for diffuse large B cell lymphoma. Ann
Hematol. 91:553–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
